Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
Subscribe To Our Newsletter & Stay Updated
